The combination of potent HbA1c reduction, minimal hypoglycemia risk, and cardiovascular benefit makes these agents the preferred glucose-lowering option for most patients with type 2 diabetes
These include leptin sensitizers, Y2R agonists (Eli Lilly, Novo Nordisk), amylin/calcitonin dual agonists (Nordic Biosciences, Amylin Pharmaceuticals), and ghrelin-targeting agents (Noxxon, Cytos) Novel mechanisms : There are several companies taking differentiated (non-incretin) approaches to obesity
[12] It can show up as fatigue, less interest in hobbies, or a general blah mood
Questionable Claims Made by Sellers TGA Approval Misrepresentation : The product claims to be TGA approved, but there is no publicly available listing of it with the Therapeutic Goods Administration of Australia
For patients looking for additional support in targeting belly fat and controlling cravings, we offer HCG and Compounded Semaglutide* as add-ons to both programs